Bladder Cancer Stage Development, 2004-2014 in Europe Compared With the United States: Analysis of European Population-based Cancer Registries, the United States SEER Database, and a Large Tertiary Institutional Cohort.

Abstract:

BACKGROUND:The purpose of this study was to analyze trends of bladder cancer (BC) stages and incidence in Europe and the United States (US). MATERIALS AND METHODS:Tumor stages after radical cystectomy were assessed in a monocentric cohort from 2006 to 2016. BC incidence was assessed between 2004 and 2014 based on the German Center for Cancer Registry Data dataset at the Robert Koch Institute (n = 111,002), the Netherland Cancer Registry (n = 64,226), cancer registration statistics of England (n = 179,883), and the pooled data from the Scandinavian cancer registries, NORDCAN (n = 77,585) and the SEER (Surveillance, Epidemiology, and End Results) database (n = 184,519) for the complete populations and gender-specific subgroups. The average annual percent changes (AAPC) were used for statistical evaluation. RESULTS:Non-muscle-invasive BC (NMIBC) and muscle-invasive BC (MIBC) did not change in the institutional cohort at the point of radical cystectomy. The incidence of total BC (AAPC, -0.3), NMIBC (AAPC, -0.1), and non-metastasized MIBC (AAPC, 0.1) did not change in Germany during the time period under survey. BC total incidence in the Netherlands did not change significantly. In England and the Nordic countries, the incidence of total BC increased (AAPC, 0.8 and 0.5, respectively). In contrast, both the incidence of total BC (AAPC, -1.4), NMIBC (AAPC, -1.6), and non-metastasized MIBC (AAPC, -1.6) significantly decreased in the US. CONCLUSIONS:Between 2004 and 2014 the incidence of BC was significantly sinking in the US, was stable in Germany and the Netherlands, and increased in England and the Nordic countries. Predominantly, differences in the smoking prevalence within the last decades but also gender-specific factors might be responsible for this discrepancy.

journal_name

Clin Genitourin Cancer

authors

Schulz GB,Grimm T,Buchner A,Jokisch F,Kretschmer A,Stief CG,Knüchel R,Kraywinkel K,Karl A

doi

10.1016/j.clgc.2019.10.008

subject

Has Abstract

pub_date

2020-06-01 00:00:00

pages

162-170.e4

issue

3

eissn

1558-7673

issn

1938-0682

pii

S1558-7673(19)30312-X

journal_volume

18

pub_type

杂志文章
  • Unravelling Adrenal Oncocytic Neoplasm.

    abstract::Oncocytic neoplasms are rare tumors arising in the adrenal glands and usually considered as nonfunctional and benign. We report 4 cases of adrenal oncocytic neoplasm. The paucity of literature describing this entity increases the chance for misdiagnosis. Confirmatory diagnosis is by tissue sampling with adrenalectomy ...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.clgc.2018.10.011

    authors: Virarkar M,Patnana M,Vikram R,Bhargava P,Birkenfeld E,Sagebiel T

    更新日期:2019-02-01 00:00:00

  • National trends in the recommendation of radiotherapy after prostatectomy for prostate cancer before and after the reporting of a survival benefit in March 2009.

    abstract:BACKGROUND:Three randomized trials demonstrated that postprostatectomy adjuvant radiotherapy improves biochemical disease-free survival for patients with adverse pathologic features, and 1 trial found adjuvant radiotherapy improves overall survival. We sought to determine whether postprostatectomy radiotherapy (PPRT) u...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2014.12.005

    authors: Mahal BA,Hoffman KE,Efstathiou JA,Nguyen PL

    更新日期:2015-06-01 00:00:00

  • Safety and efficacy of maintenance therapy with a nonspecific cytochrome P17 inhibitor (CYP17i) after response/stabilization to docetaxel in metastatic castration-resistant prostate cancer.

    abstract:BACKGROUND:Frontline treatment of metastatic castration-resistant prostate cancer (mCRPC) consists of docetaxel-based chemotherapy. The median time to progression (TTP) from chemotherapy initiation is 6 to 8 months. Ketoconazole, a nonspecific cytochrome P17 inhibitor (CYP17i), blocks adrenal androgen synthesis. Low-do...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2012.11.003

    authors: Gil-Bazo I,Arévalo E,Castillo A,Zudaire ME,Carranza OE,Fusco JP,Castañón E,Collado-Gómez V,López I,Gil-Aldea I

    更新日期:2013-06-01 00:00:00

  • Evaluation of Gleason Grade Group 5 in a Contemporary Prostate Cancer Grading System and Literature Review.

    abstract:INTRODUCTION:The aim of this study was to validate contemporary grading systems, in particular, the Gleason grade group (GGG) 5. PATIENTS AND METHODS:We retrospectively reviewed the clinicopathologic data of 176 patients who underwent radical prostatectomy and whose pathologic results were GGG 4 or 5. The endpoints we...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2020.08.001

    authors: Kamitani R,Matsumoto K,Kosaka T,Takeda T,Hashiguchi A,Tanaka N,Morita S,Mizuno R,Shinojima T,Asanuma H,Oya M

    更新日期:2020-08-07 00:00:00

  • Results of a Real-world Study of Enzalutamide and Abiraterone Acetate With Prednisone Tolerability (REAAcT).

    abstract:BACKGROUND:The objective of this study was to evaluate differences in tolerability in patients with metastatic castration-resistant prostate cancer treated with enzalutamide (ENZA) or abiraterone acetate plus prednisone (AA+P). PATIENTS AND METHODS:This was a phase IV, prospective, open-label, multicenter, real-world ...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.clgc.2019.07.017

    authors: Shore ND,Saltzstein D,Sieber P,Mehlhaff B,Gervasi L,Phillips J,Wong YN,Pei H,McGowan T

    更新日期:2019-12-01 00:00:00

  • Associations Between Prostate Volume and Oncologic Outcomes in Men Undergoing Focal Cryoablation of the Prostate.

    abstract:INTRODUCTION:The purpose of this study was to assess the relationship of total prostate volume (TPV) and oncologic outcomes following focal prostate cryoablation. MATERIALS AND METHODS:A query of the Cryo On-Line Database (COLD) registry for men who underwent primary focal prostate cryoablation revealed 829 patients w...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.clgc.2017.10.009

    authors: Elshafei A,Tay KJ,Kara O,Malkoc E,Nyame Y,Arora H,Hatem A,Patel SA,Lugnani F,Polascik TJ,Jones JS

    更新日期:2018-04-01 00:00:00

  • Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell Carcinoma.

    abstract:INTRODUCTION:The objective of this study was to determine the effectiveness and safety of pazopanib in patients with intermediate-risk advanced/metastatic renal cell carcinoma in the PRINCIPAL study (NCT01649778). PATIENTS AND METHODS:Patients had clear-cell advanced/metastatic renal cell carcinoma and met intermediat...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2019.01.018

    authors: Procopio G,Bamias A,Schmidinger M,Hawkins R,Sánchez AR,Estevez SV,Srihari N,Kalofonos H,Bono P,Pisal CB,Hirschberg Y,Dezzani L,Ahmad Q,Rodriguez CS,Jonasch E

    更新日期:2019-06-01 00:00:00

  • Influence of body mass index and smoking on the long-term survival of patients with renal cell cancer.

    abstract:BACKGROUND:Smoking and obesity are known risk factors for renal cell carcinoma (RCC). We determined the influence of smoking, body mass index (BMI), and symptoms on the survival of patients with RCC. PATIENTS AND METHODS:In this retrospective study, the relative overall survival (OS) up to 25 years was calculated amon...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2013.04.017

    authors: Sunela KL,Kataja MJ,Kellokumpu-Lehtinen PL

    更新日期:2013-12-01 00:00:00

  • Histopathologic Characteristics of Upper Tract Urothelial Carcinoma With an Emphasis on Their Effect on Cancer Survival: A Single-Institute Experience With 305 Patients With Long-Term Follow-Up.

    abstract:INTRODUCTION:Tumor stage and grade represent the best established predictors for the prognosis of upper tract urothelial carcinoma (UTUC). However, controversies still exist regarding the role of tumor necrosis, location, and multifocality in the prognosis of UTUC. We share our experience with 305 patients, reporting o...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2016.04.017

    authors: Elawdy MM,Taha DE,Elbaset MA,Abouelkheir RT,Osman Y

    更新日期:2016-12-01 00:00:00

  • Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinoma.

    abstract:BACKGROUND:The complete remission (CR) rate with salvage systemic therapy for urothelial carcinoma (UC) is unclear, and its value as an intermediate end point and association with survival are unknown. MATERIALS AND METHODS:Data from phase II trials of salvage chemotherapy and/or biologic agents were pooled. Data rega...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2014.09.004

    authors: Sonpavde G,Pond GR,Rosenberg JE,Bajorin DF,Regazzi AM,Choueiri TK,Qu AQ,Niegisch G,Albers P,Necchi A,Di Lorenzo G,Fougeray R,Dreicer R,Chen YH,Wong YN,Sridhar SS,Ko YJ,Milowsky MI,Galsky MD,Bellmunt J

    更新日期:2015-04-01 00:00:00

  • Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer.

    abstract:BACKGROUND:Cisplatin-based neoadjuvant chemotherapy (NAC) before cystectomy improves survival in muscle-invasive urothelial bladder cancer (MIBC). The use of NAC before chemoradiation (CRT) has been limited, as these patients are often elderly, frail, and ineligible for cisplatin. However, the role of NAC in fit, cispl...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2018.09.021

    authors: Jiang DM,Jiang H,Chung PWM,Zlotta AR,Fleshner NE,Bristow RG,Berlin A,Kulkarni GS,Alimohamed NS,Lo G,Sridhar SS

    更新日期:2019-02-01 00:00:00

  • Sociodemographic Disparities in the Nonoperative Management of Small Renal Masses.

    abstract:BACKGROUND:Local tumor ablation (LTA) and expectant management (EM) represent competing treatment modalities for patients with small renal masses (SRMs) who are unfit for surgery. We examined the potential social discrepancies in the access of LTA and EM. MATERIALS AND METHODS:A total of 1860 patients with cT1a kidney...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2015.10.011

    authors: Trudeau V,Larcher A,Sun M,Boehm K,Dell'Oglio P,Meskawi M,Sosa J,Tian Z,Fossati N,Briganti A,Karakiewicz PI

    更新日期:2016-04-01 00:00:00

  • Spontaneous intraperitoneal perforation of the bladder: a late complication of radiation therapy for prostate cancer.

    abstract::The spontaneous intraperitoneal rupture of the urinary bladder is an extremely rare and life-threatening event. Often, there are difficulties in establishing the diagnosis. A patient with spontaneous perforation of the urinary bladder, 17 years after successful treatment of an adenocarcinoma of the prostate by pelvic ...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.3816/CGC.2007.n.006

    authors: Ketata S,Boulaire JL,Al-Ahdab N,Bargain A,Damamme A

    更新日期:2007-03-01 00:00:00

  • Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer.

    abstract:BACKGROUND:Level 1 evidence has demonstrated increased overall survival with cisplatin-based neoadjuvant chemotherapy for patients with muscle-invasive urothelial cancer. Usage remains low, however, in part because neoadjuvant chemotherapy will not be effective for every patient. To identify the patients most likely to...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.clgc.2016.03.006

    authors: O'Donnell PH,Alanee S,Stratton KL,Garcia-Grossman IR,Cao H,Ostrovnaya I,Plimack ER,Manschreck C,Ganshert C,Smith ND,Steinberg GD,Vijai J,Offit K,Stadler WM,Bajorin DF

    更新日期:2016-12-01 00:00:00

  • Impact of Bladder Neck Involvement on Recurrence in Patients With Non-muscle-invasive Bladder Cancer: An Analysis Based on a Time-dependent Model.

    abstract:BACKGROUND:Tumor location in bladder neck has reported to be a prognostic factor for non-muscle-invasive bladder cancer (NMIBC). We investigated the impact of bladder neck involvement (BNI) on recurrence in NMIBC using time-dependent covariate analysis. PATIENTS AND METHODS:We enrolled 585 Japanese patients who underw...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2019.10.005

    authors: Waseda Y,Kobayashi S,Kanda E,Yokoyama M,Ishioka J,Matsuoka Y,Saito K,Fujii Y

    更新日期:2020-04-01 00:00:00

  • Adjuvant therapy of renal cell carcinoma.

    abstract::Metastatic renal cell carcinoma (RCC) has a highly variable natural history and carries a dismal prognosis. Unlike many other tumors, RCC is generally unresponsive to cytotoxic, hormonal, and radiation adjuvant therapies after cytoreductive surgery. Different modalities of treatment have been tried and tested with mod...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,评审

    doi:10.3816/CGC.2006.n.028

    authors: Yap TA,Eisen TG

    更新日期:2006-09-01 00:00:00

  • New Treatment Options for Patients With Metastatic Prostate Cancer: What Is The Optimal Sequence?

    abstract::Systemic treatment of men with metastatic prostate cancer is rapidly evolving. Androgen deprivation therapy remains the first-line treatment for advanced disease and the backbone of sequential strategies. For patients with extensive metastatic disease the addition of docetaxel markedly improves survival. In case patie...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.clgc.2015.01.008

    authors: van Dodewaard-de Jong JM,Verheul HMW,Bloemendal HJ,de Klerk JMH,Carducci MA,van den Eertwegh AJM

    更新日期:2015-08-01 00:00:00

  • A Systematic Review and Network Meta-analysis of Novel Androgen Receptor Inhibitors in Non-metastatic Castration-resistant Prostate Cancer.

    abstract:BACKGROUND:Among men with high-risk non-metastatic castrate-resistant prostate cancer (nmCRPC), we used network meta-analysis to compare non-steroidal anti-androgens (NSAAs) and stratified class-level meta-analysis to identify subgroups with particular benefit from NSAAs with androgen deprivation therapy versus androge...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.clgc.2020.02.005

    authors: Hird AE,Magee DE,Bhindi B,Ye XY,Chandrasekar T,Goldberg H,Klotz L,Fleshner N,Satkunasivam R,Klaassen Z,Wallis CJD

    更新日期:2020-10-01 00:00:00

  • Neoadjuvant Radiotherapy Improves Survival in Patients With T2b/T3 Bladder Cancer: A Population-Based Analysis.

    abstract:BACKGROUND:Neoadjuvant radiotherapy (NART) for muscle-invasive bladder cancer (MIBC) is currently underused. However, the outcomes for MIBC have remained suboptimal. We investigated the relationship of NART to cause-specific mortality (CSM) and overall mortality (OM) among patients with a diagnosis of MIBC. MATERIALS ...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2015.02.014

    authors: Diaz DA,Pollack A,Reis IM,Mahmoud O,Gonzalgo ML,Ishkanian A,Fernandez G,Manoharan M,Abramowitz MC

    更新日期:2015-08-01 00:00:00

  • Location of Metastases in Contemporary Prostate Cancer Patients Affects Cancer-Specific Mortality.

    abstract:PURPOSE:To quantify the prognostic effect of the location of prostate cancer (PCa) metastases on cancer-specific mortality (CSM) and the rate of other-cause mortality (OCM) in contemporary newly diagnosed metastatic PCa (mPCa) patients. PATIENTS AND METHODS:Within the Surveillance Epidemiology and End Results database...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2018.05.016

    authors: Mazzone E,Preisser F,Nazzani S,Tian Z,Bandini M,Gandaglia G,Fossati N,Soulières D,Graefen M,Montorsi F,Shariat SF,Saad F,Briganti A,Karakiewicz PI

    更新日期:2018-10-01 00:00:00

  • Comparative Effectiveness of Intravesical BCG-Tice and BCG-Moreau in Patients With Non-muscle-invasive Bladder Cancer.

    abstract:BACKGROUND:The purpose of this study was to compare the efficacy of 2 bacillus Calmette-Guérin (BCG) strains, BCG-Tice and BCG-Moreau, in the treatment of non-muscle-invasive bladder cancer (NMIBC). MATERIALS AND METHODS:We retrospectively reviewed clinical data from patients treated with BCG for NMIBC at 3 academic c...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.clgc.2019.10.021

    authors: D'Andrea D,Soria F,Abufaraj M,Pones M,Gontero P,Machado AT,Waksman R,Enikeev DV,Glybochko PV,Adonias SP,Nahas WC,Shariat SF,Chade DC

    更新日期:2020-02-01 00:00:00

  • Metabolic syndrome as a peculiar target for management of prostate cancer patients.

    abstract::An interesting and reciprocal association between the metabolic syndrome and prostate cancer has been identified. Metabolic alterations, such as hyperinsulinemia, increased levels of insulin growth factor-1, and insulin resistance could be on the basis of development and progression of many tumors, including prostate ...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.clgc.2013.04.009

    authors: Conteduca V,Di Lorenzo G,Bozza G,Ardito R,Aieta M

    更新日期:2013-09-01 00:00:00

  • Serum Proteomics on the Basis of Discovery of Predictive Biomarkers of Response to Androgen Deprivation Therapy in Advanced Prostate Cancer.

    abstract:BACKGROUND:We investigated the serum proteome of hormone-sensitive prostate cancer patients to determine candidate biomarkers associated with androgen deprivation therapy (ADT) efficacy. PATIENTS AND METHODS:Serum proteomes generated using isobaric mass tags for relative and absolute quantitation were analyzed using r...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2019.03.006

    authors: Kohli M,Oberg AL,Mahoney DW,Riska SM,Sherwood R,Zhang Y,Zenka RM,Sahasrabudhe D,Qin R,Zhang S

    更新日期:2019-08-01 00:00:00

  • Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor-Targeted Agents.

    abstract:BACKGROUND:Several agents have demonstrated an overall survival (OS) benefit in patients with metastatic castration-resistant prostate cancer (mCRPC); however, the optimal sequencing of these therapies is unknown as a result of a lack of prospective randomized controlled trials. This retrospective study aimed to identi...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.clgc.2018.02.016

    authors: Angelergues A,Efstathiou E,Gyftaki R,Wysocki PJ,Lainez N,Gonzalez I,Castellano DE,Ozguroglu M,Carbonero IG,Flechon A,Borrega P,Guillot A,Balea BC,Le Moulec S,Esteban E,Munarriz J,Rubio G,Birtle AJ,Delanoy N,Bellmunt

    更新日期:2018-08-01 00:00:00

  • Impact of enzalutamide administration on primary prostate cancer volume: a metabolic evaluation by choline positron emission tomography in castration-resistant prostate cancer patients.

    abstract:BACKGROUND:Enzalutamide is active in advanced castration-resistant prostate cancer (CRPC) patients, in whom it has shown to be able to increase survival. We report the enzalutamide effect on primary prostate tumors, assessed by changes of metabolic tumor activity detected by (18)F-fluorocholine-positron emission tomogr...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2014.03.004

    authors: Caffo O,Maines F,Donner D,Veccia A,Chierichetti F,Galligioni E

    更新日期:2014-10-01 00:00:00

  • The R.E.N.A.L. nephrometric nomogram cannot accurately predict malignancy or aggressiveness of small renal masses amenable to partial nephrectomy.

    abstract:INTRODUCTION/BACKGROUND:The prediction of histology of SRM could be essential for their management. The RNN is a statistical tool designed to predict malignancy or high grading of enhancing renal masses. In this study we aimed to perform an external validation of the RNN in a cohort of patients who received a PN for SR...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.clgc.2014.02.003

    authors: Antonelli A,Furlan M,Sandri M,Minervini A,Cindolo L,Parma P,Zaramella S,Porreca A,Vittori G,Samuelli A,Dente D,Berardinelli F,Raspollini MR,Serni S,Carini M,Terrone C,Schips L,Simeone C

    更新日期:2014-10-01 00:00:00

  • Effect of perioperative blood transfusion on mortality for major urologic malignancies.

    abstract:INTRODUCTION:Patients who undergo surgical treatment for malignancy often receive perioperative blood transfusion (PBT). We examined the association between PBT and mortality in patients who received surgical treatment of prostate, bladder, and kidney cancer. MATERIALS AND METHODS:Using the Surveillance, Epidemiology,...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2014.12.006

    authors: Soubra A,Zabell JR,Adejoro O,Konety BR

    更新日期:2015-06-01 00:00:00

  • A phase II study of depsipeptide in refractory metastatic renal cell cancer.

    abstract:BACKGROUND:Therapeutic options for renal cell cancer are inadequate. Depsipeptide is a histone deacetylase inhibitor with promising preclinical and early clinical activity. PATIENTS AND METHODS:Patients with refractory renal cell cancer with normal organ function and no history of significant cardiovascular disease we...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,多中心研究

    doi:10.3816/CGC.2006.n.018

    authors: Stadler WM,Margolin K,Ferber S,McCulloch W,Thompson JA

    更新日期:2006-06-01 00:00:00

  • Pathologic Predictors of Survival During Lymph Node Dissection for Metastatic Renal-Cell Carcinoma: Results From a Multicenter Collaboration.

    abstract:PURPOSE:To determine the therapeutic value of lymph node dissection (LND) during cytoreductive nephrectomy (CN) and assess predictors of cancer-specific survival (CSS) in metastatic renal-cell carcinoma. PATIENTS AND METHODS:We identified 293 consecutive patients treated with CN at 4 academic institutions from March 2...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.clgc.2017.10.004

    authors: Chipollini J,Abel EJ,Peyton CC,Boulware DC,Karam JA,Margulis V,Master VA,Zargar-Shoshtari K,Matin SF,Sexton WJ,Raman JD,Wood CG,Spiess PE

    更新日期:2018-04-01 00:00:00

  • Risk-Stratified Initial Salvage Therapy for Relapsed or Refractory Metastatic Germ Cell Tumors.

    abstract:BACKGROUND:Salvage treatment with either conventional-dose chemotherapy (CDCT) or high-dose chemotherapy with autologous stem cell transplantation (HDCT) offers curative potential for patients with relapsed or refractory germ cell tumor (GCT). However, the optimal initial salvage strategy remains controversial, and the...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2016.03.015

    authors: Narayan V,Gunnarsson O,Hwang WT,Squillante CM,Nathanson KL,Stadtmauer EA,Vaughn DJ

    更新日期:2016-12-01 00:00:00